Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How to Manage Revenue Losses Due to COVID-19 While Continuing to Supply Essential Community Services.

The most prominent topic in healthcare today is COVID-19. All healthcare areas felt the pandemic’s effects, and no practice was immune to the financial challenges resulting from the virus. Mary Tucker, CEO of UPIC Health, brought together a panel of healthcare experts to discuss these challenges and get some insights on how practices can…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
How to Manage Revenue Losses Due to COVID-19 While Continuing to Supply Essential Community Services.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The most prominent topic in healthcare today is COVID-19. All healthcare areas felt the pandemic’s effects, and no practice was immune to the financial challenges resulting from the virus.

Mary Tucker, CEO of UPIC Health, brought together a panel of healthcare experts to discuss these challenges and get some insights on how practices can manage to continue providing essential community services while battling the virus. Dr. Jamal Mahdavian, Solo Practitioner in General Surgeon, Health Alliance of the Hudson Valley in Kingston, NY, Dr. Gary Smalto, Vice President at Optum Advisory Services and Practice Partner Health System Performance Improvement, and Kevin Sexton, Managing Director of the Berkeley Research Group and retired CEO of Holy Cross Health, joined Tucker to talk about healthcare’s current state.

Sexton viewed the COVID-19 experience as a stress-test for the entire healthcare system.

“I would say there are three or four things we need to take a look at seriously going forward,” Sexton said.

He noted that, when the pandemic halted elective procedures during the spring, that placed a huge financial burden on the system and showed the healthcare industry’s fragility. The pandemic also uncovered the disparity in care for certain underserved groups in the United States.

“The net result was the system got in trouble, and we didn’t do a great job of delivering care and at least getting equal results for people in need,” he said.

Dr. Mahdavian pointed out that the United States’ employer-based insurance system also became an issue during the pandemic.

“As soon as you lost your job, you lost your insurance, at least within a certain amount of time. Most blue-collar jobs can’t be done from home,” Mahdavian said. “Even in the medical profession, itself, there is no ‘at home surgery.’”

“We’ve used our medical system as a way to treat case-by-case,” Dr. Smalto said. “And we really haven’t thought about covering populations. And what we’ve learned with COVID is that organizations, particularly healthcare systems that had risk contracts and populations under risk already, did better than organizations that primarily had fee for service. What that shows you is that fee for service is a risk model, and we didn’t know it.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512